Public Policy

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth. Mr. Waddill provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs hearing.

The 2011 BIO International Convention brought together over 15,000 leaders from industry, government and academia who are working to solve some of the sector's biggest challenges. We were honored to host governors from 11 U.S. states as they promote their bioscience economic development endeavors.

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world.

New Orleans shows the signs of a city reborn from the destruction brought on by Hurricane Katrina.  The changes in the city’s infrastructure and building projects have certainly been among them.  The city reached a  milestone its renaissance when the New Orleans BioInnovation Center (NOBIC) opened for business.

Regulatory review processes are not keeping up with rapidly advancing science and are making the environment for developing new treatments and preventions for deadly and debilitating diseases more difficult.